Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Bearish
3
Neutral
6
Bullish
5
Bearish
35
Neutral
6
Bullish
5
Bearish
32
Neutral
0
Bullish
0
Bearish
3
Neutral
6
Bullish
5
Bearish
3
Neutral
6
Bullish
5
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Oxygenta Pharmaceutical Limited, formerly S S Organics Ltd, specializes in manufacturing anti-ulcerative and antibacterial drugs, alongside other pharmaceuticals.
The company engages in both contract manufacturing and independent production, supporting its revenue through strategic partnerships.
Oxygenta's production facilities are situated in Medak, Andhra Pradesh, focusing on bulk drugs, including quinolones, antiasthmatic, and anti-inflammatory medications.
Despite operational challenges, such as the 2015 fire accident, Oxygenta has resumed commercial production to stabilize its operations and market position.
Pharmaceuticals & Biotechnology
Pharmaceuticals
170 Cr
Moderate Risk
-12.6
34.8
—
—
71.59
43.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
131.25 | 179 Cr | -6.78 | 7.50 | 0.00 | -148.86 | -9.23 | -19.10 | ||
494.10 | 176 Cr | 9.18 | 0.84 | 0.40 | 7.83 | 10.89 | 7.98 | ||
58.02 | 171 Cr | 12.94 | 1.39 | 0.00 | 20.04 | 19.30 | 8.92 | ||
46.07 | 170 Cr | -12.56 | 0.00 | 0.00 | 41.16 | -26.02 | -11.34 | ||
6.96 | 168 Cr | 524.94 | 4.79 | 0.00 | 0.90 | 1.13 | 0.84 | ||
20.17 | 167 Cr | 12.11 | 2.22 | 0.00 | 17.38 | 20.98 | 9.01 | ||
31.03 | 166 Cr | 27.10 | 1.16 | 0.00 | 8.93 | 13.60 | 2.10 | ||
| Median: 7 Co. | — | 46.07 | 170 Cr | 12.11 | 1.39 | 0.00 | 8.93 | 10.89 | 2.10 |
Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is currently trading at 46.07 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Oxygenta Pharmaceutical Limited, formerly S S Organics Ltd, specializes in manufacturing anti-ulcerative and antibacterial drugs, alongside other pharmaceuticals. The company engages in both contract manufacturing and independent production, supporting its revenue through strategic partnerships. Oxygenta's production facilities are situated in Medak, Andhra Pradesh, focusing on bulk drugs, including quinolones, antiasthmatic, and anti-inflammatory medications. Despite operational challenges, such as the 2015 fire accident, Oxygenta has resumed commercial production to stabilize its operations and market position.
Over the past 52 weeks, Oxygenta Pharmaceutical Ltd has traded between a low of ₹43.00 and a high of ₹71.59. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Oxygenta Pharmaceutical Ltd has a market capitalization of approximately 170.38. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Oxygenta Pharmaceutical Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -12.56 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 170.38 Cr, Oxygenta Pharmaceutical Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Oxygenta Pharmaceutical Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Oxygenta Pharmaceutical Ltd is -12.56. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
